AB

Abliva ABSTO Abliva Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

0.029

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

ABLI.ST Stock Analysis

AB

Uncovered

Abliva AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-2/100

Low score

Market cap $B

0.029

Dividend yield

Shares outstanding

1 056.3 B

Abliva AB operates as a biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. The company is headquartered in Lund, Skane. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.

View Section: Eyestock Rating